Opinion
Video
This program was possible with support from Bayer.
Prostate Cancer Prognosis and Risk Stratification
Author(s):
Rashid K. Sayyid, MD, MSc, describes the staging and risk stratification process for patients with prostate cancer and their effect on prognosis.
This is a synopsis of an Educated Patient Sound Bites series featuring Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute; Rashid K. Sayyid, MD, MSc, of the University of Toronto; and Reginald Tucker-Seeley, MA, ScM, ScD, of ZERO Prostate Cancer.
In this transcript, Rashid K. Sayyid, MD, MSc, a urologic oncology fellow at the University of Toronto, offers insights on prostate cancer. He first discusses disease staging, categorizing prostate cancer into localized, locally advanced, and metastatic disease. Dr Sayyid notes treatment implications and prognosis by stage, stating localized and locally advanced disease generally have good 10-year prognosis while metastatic disease ranges from 3-8 years depending on extent of metastases.
Dr Sayyid then addresses risk stratification, stating the National Comprehensive Cancer Network (NCCN) classification system categorizes patients from very low to high risk, impacting treatment decisions. This classification uses variables like Gleason score, prostate-specific antigen (PSA) level, clinical stage, biopsy positivity percentage, and imaging findings.
In summarizing key points, Dr. Rashid K. Sayyid covers disease staging, prognosis, risk classification, and treatment implications for prostate cancer patients. He highlights emerging treatments improving prognosis, especially for metastatic disease.
*Video synopsis is AI-generated and reviewed by CURE editorial staff.
